Economics of reimportation and risks of counterfeit pharmaceuticals
Lybecker, K.M.
Managed Care 13(3 Suppl): 10-13
2004
ISSN/ISBN: 1062-3388 PMID: 15074163 Document Number: 579593
Document emailed within 1 workday
Related Documents
Sugita, M.; Miyakawa, M. 2010: Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example Environmental Health and Preventive Medicine 15(4): 244-251Sugita, M.; Miyakawa, M. 2010: Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example Environmental Health and Preventive Medicine 15(4): 244-251
Macdonald, R J. 2012: On the Role of Paradigms in Finance; From Economics Imperialism to Freakonomics: The Shifting Boundaries between Economics and Other Social Sciences; Economics Versus Human Rights Review of Social Economy 70(1): 134-141
Gouveia, W.A. 1993: The rising cost of pharmaceuticals: understanding and managing the escalating cost of pharmaceuticals in health care institutions. Executive summary American Journal of Hospital Pharmacy 50(8 Suppl. 4): S2-S3
Lobb, W.B.; Wilkin, N.E.; Holmes, E.R. 2015: Pharmacists' Perceptions of the Economic Value of Compounded Pharmaceuticals: a Comparison of Compounded and Commercial Pharmaceuticals in Select Disease States International Journal of Pharmaceutical Compounding 19(6): 514-520
Mattison, N. 2004: European parallel trade: lessons for reimportation Managed Care 13(6 Suppl): 35-37; Discussion: 40-42
Watson, R. 2002: EU clamps down on reimportation of cheap drugs meant for Africa Bmj 325(7372): 1058
Jurista, J. 1979: Development and characteristics of scientific and research work of the department of economics and management of agriculture at the Bratislava School of Economics Zemedelska ekonomika 25(5): 365-368
Greenlick, M.R. 1974: The scope and bounds of health economics and medical economics Israel Journal of Medical Sciences 10(1): 81-95
Roush, W. 1997: Counterfeit chromosomes for humans Science 276(5309): 38-39
Williamson, L. 2014: Counterfeit drugs are everyone's business Krankenpflege. Soins Infirmiers 107(7): 72-73
Williamson, L. 2014: Counterfeit drugs are everyone's business KRANKENPFLEGE. Soins Infirmiers 107(8): 22-23
Martin, J.; Kauer, S.D.; Sanci, L. 2016: Road safety risks in young people attending general practice: A cross-sectional study of road risks and associated health risks Australian Family Physician 45(9): 666-672
Volans, G.N. 1992: Counterfeit medicines--the case for action Adverse Drug Reactions and Toxicological Reviews 11(1): 3
Kang, S.; Zhou, C.; He, Y.; Zhang, J.; Wei, A.-h.; Lu, J.; Ma, S.-c. 2015: Identification of Epmedii Folium and its counterfeit leaf of Quercus variabilis Zhongguo Zhong Yao Za Zhi 40(9): 1676-1680
Amon, J.J. 2008: Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs Globalization and Health 4: 5
Tamir, O.; Friedman, N.; Furman-Assaf, S.; Marom, E.; Arieli, M.; Shemer, J. 2010: Counterfeit drugs in Israel and worldwide. Part I: the extent of occurrence and impending threats Harefuah 149(7): 466-469; 479
Dai, X.-m.; An, N.; Wu, J.-m.; Li, H.-y.; Zhang, Q.-m. 2010: Development and validation of HPLC-UV-MS method for the control of four anti-diabetic drugs in suspected counterfeit products Yao Xue Xue Bao 45(3): 347-352
Cuchet-Chosseler, M.; Bocoum, O.; Camara, M.; Abad, B.; Yamani, E. 2011: Results of a survey to evaluate the efficacy of a regional awareness campaign on counterfeit street medicines in Bamako, Mali and Nouakchott, Mauritania Medecine Tropicale: Revue du Corps de Sante Colonial 71(2): 152-156
Ray, D.E. 2000: Pesticide neurotoxicity in Europe: real risks and perceived risks Neurotoxicology 21(1-2): 219-221